drugset / Trial / NCT07144735
Allogeneic γδT Cells in Glioblastoma
Recruiting
18 enrolled
Peking University Third Hospital
Changping Laboratory · collabPeking University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2027-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic γδ T (ABOUT) cells | Cell therapy | 7e+07 cells | Other |
| Subject | Allogeneic γδ T (ABOUT) cells | Cell therapy | 1.1e+08 cells | Other |
| Subject | Allogeneic γδ T (ABOUT) cells | Cell therapy | 1.6e+08 cells | Other |